ACHN 2018 Proxy Statement

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END The following table sets forth information concerning outstanding stock options on December 31, 2017, the last day of our fiscal year, for each of the named executive officers. Option Awards(1) Name Number of Securities Underlying Unexercised Options (#) Exercisable Number of Securities Underlying Unexercised Options (#) Unexercisable Option Exercise Price ($) Option Expiration Date Milind Deshpande, Ph.D. . . . . . . . . . . 75,576 — 3.10 12/16/2020 Director and Chief Executive Officer 100,000 — 7.59 12/12/2021 145,000 — 8.64 12/18/2022 600,000 — 7.59 05/28/2023 300,000 — 3.02 12/17/2023 258,750 86,250 13.24 12/02/2024 175,000 225,000 7.61 01/20/2026 — 458,000 4.11 01/17/2027 Mary Kay Fenton . . . . . . . . . . . . . . . . . 33,250 — 3.28 12/18/2019 Executive Vice President, Chief Financial Officer and Treasurer 188,000 — 3.10 12/16/2020 75,000 — 7.59 12/12/2021 145,000 — 8.64 12/18/2022 250,000 — 3.02 12/17/2023 28,125 1,875 3.66 03/04/2024 82,500 27,500 13.24 12/02/2024 51,625 66,375 7.61 01/20/2026 — 165,000 4.11 01/17/2027 Martha Manning . . . . . . . . . . . . . . . . . 48,125 61,875 6.79 02/21/2026 Executive Vice President, General Counsel and Corporate Secretary — 135,000 4.11 01/17/2027 Joseph Truitt . . . . . . . . . . . . . . . . . . . . 33,250 — 3.28 12/18/2019 President and Chief Operating Officer 188,000 — 3.10 12/16/2020 100,000 — 7.59 12/12/2021 145,000 — 8.64 12/18/2022 200,000 — 3.02 12/17/2023 28,125 1,875 3.66 03/04/2024 82,500 27,500 13.24 12/02/2024 62,125 79,875 7.61 01/20/2026 — 185,000 4.11 01/17/2027 David Apelian, M.D., Ph.D. (2) . . . . . . 200,000 — 7.59 03/28/2018 Former Executive Vice President and Chief Medical Officer 290,000 — 3.02 03/28/2018 131,250 — 13.24 03/28/2018 51,625 — 7.61 03/28/2018 Joel Barrish, Ph.D.(3) . . . . . . . . . . . . . — — — — Former Executive Vice President and Chief Scientific Officer (1) The options granted have a ten year life and vest over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three-month period thereafter, subject to continued service. In addition, upon a change in control, each of Dr. Deshpande, Ms. Fenton, Ms. Manning, and Mr. Truitt are entitled to immediate vesting and exercisability of 50% of the original number of shares subject to unvested option grants. In the event we terminate such executive’s employment for reasons other than cause, death or disability, or if such executive terminates his employment for good reason, within twelve months following a change in control of the company, then each executive officer is entitled to immediate vesting and exercisability of all outstanding options, restricted stock and restricted stock units. (2) Dr. Apelian ceased to be an employee on December 28, 2017. Dr. Apelian’s right to exercise his outstanding exercisable options terminated three months from his date of termination, or March 28, 2018. (3) Dr. Barrish ceased to be an employee on July 14, 2017. 49